drugset / Trial / NCT04392128
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.
Timeline
- Start
- 2020-09-02
- Primary completion
- 2020-09-02
- Completion
- 2020-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | — |